The influenza epidemic has driven an increase in demand for oseltamivir, and related products of Dongyang Pharmaceutical have been included in medical insurance

2026-11-22 10:57

Economic Observation Network Dongyangguang Pharmaceutical (06887. HK) has sufficient production capacity to quickly respond to the demand for medication during the flu season, and its Olagliflozin capsules have been included in the 2026 version of the national medical insurance catalog.

Business Progress
The positive rate of influenza virus in the 46th week of China CDC (11-09 to 11-15) was 22.5%, rising for four consecutive weeks, and the country has entered a moderate epidemic level; Dingdang Quick Medicine Platform Oseltamivir Week on Week Sales+77% The company stated that its full production capacity is 3.6 billion bags of granules and 3 billion capsules, and the production line can switch from zero to full load within 3-5 days. In addition, in 2025, the external sales of Kewei exceeded the internal sales for the first time Influenza data is disclosed every Thursday/Friday, and peak season shipments will be verified in the annual report for March next year.

Progress of medical insurance directory
On November 15th, it was announced that Olagliflozin capsules would be included in the 2026 version of the national medical insurance catalog 。

The above content is based on publicly available information and does not constitute investment advice.